Suppr超能文献

COVID-19 相关呼吸衰竭的呼吸支持:经验教训。

Respiratory Support in COVID-19-Related Respiratory Failure: Lessons Learnt.

机构信息

Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.

Australian and New Zealand Intensive Care Research Centre, School of Preventive Medicine and Public Health, Monash University, Melbourne, VIC, Australia.

出版信息

Adv Exp Med Biol. 2024;1457:97-109. doi: 10.1007/978-3-031-61939-7_5.

Abstract

The COVID-19 pandemic has undeniably changed the way intensivists manage acute hypoxaemic respiratory failure. Paradigms had evolved particularly in the way we support patients with respiratory failure, and the adjunctive therapies which can be used. Many questions have been answered, and many more generated, from the last few years. For example, is COVID-19 acute respiratory failure and acute respiratory distress syndrome similar to non-COVID-19? How can we personalize therapy in patients with COVID-19, and what are some new statistical tools that we can use to aid in this approach? Is intubation and invasive mechanical ventilation the only way to support patients with acute respiratory failure, or can we turn to other modalities of respiratory support? And what about patients with the most severe form of respiratory failure, how can we support them? In this chapter, we explore the lessons learnt, identifying gaps and advances in knowledge in terms of the pathophysiology of acute respiratory failure, its prognostic factors, oxygen supports, and other therapies. We also touch on how physicians treating patients can tap on international networks to create a "whole that is more than the sum of its parts", and impart clinical insights on the management of acute respiratory failure. Finally, we highlight the importance of a cautious skepticism in our approach to both clinical medicine and evidence-based medicine, highlighting how evidence in a pandemic can rapidly evolve both within an ICU, and longitudinally around the world.

摘要

COVID-19 大流行无疑改变了重症医学专家治疗急性低氧性呼吸衰竭的方式。我们在支持呼吸衰竭患者的方式以及可以使用的辅助疗法方面已经发生了重大变化。在过去的几年中,许多问题已经得到解答,同时也产生了更多的问题。例如,COVID-19 急性呼吸衰竭和急性呼吸窘迫综合征与非 COVID-19 相似吗?我们如何针对 COVID-19 患者进行个体化治疗,以及我们可以使用哪些新的统计工具来帮助我们实现这种方法?气管插管和有创机械通气是否是支持急性呼吸衰竭患者的唯一方法,或者我们是否可以转向其他呼吸支持模式?对于呼吸衰竭最严重的患者,我们如何支持他们?在本章中,我们探讨了所学到的经验,确定了急性呼吸衰竭的病理生理学、预后因素、氧支持和其他治疗方面的知识差距和进展。我们还讨论了治疗患者的医生如何利用国际网络来实现“整体大于部分之和”,并就急性呼吸衰竭的管理提供临床见解。最后,我们强调了在临床实践和循证医学中保持谨慎怀疑的重要性,突出了在 ICU 内以及在全球范围内,证据在大流行期间如何迅速演变。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验